Health Care Supplies

ICU Medical

ICU Medical released FY2026 Q1 earnings on May 7 After-Market (EST), actual revenue USD 530.23 M (forecast USD 532.7 M), actual EPS USD 1.2 (forecast USD 0.0966)

ICU Medical Q1 Revenue Beats Estimates

ICU Medical to Release FY2026 Q1 Earnings on May 7 After-Market EST, Forecast Revenue USD 531.12 M, EPS USD 0.0966

ICU Medical Reports Improved Operations and Cash Generation in 2025 Annual Report

ICU Medical released FY2025 Q4 earnings on February 19 After-Market (EST), actual revenue USD 540.7 M (forecast USD 541.2 M), actual EPS USD -0.6373 (forecast USD -0.2166)

ICU Medical released FY2025 earnings on February 19 After-Market EST, actual revenue USD 2.231 B (forecast USD 2.221 B), actual EPS USD 0.0297 (forecast USD 0.44)

ICU Medical to Release FY2025 Q4 Earnings on February 19 After-Market EST, Forecast Revenue USD 541.2 M, EPS USD -0.2166

ICU Medical released FY2025 Q3 earnings on November 6 After-Market EST, actual revenue USD 536.99 M (forecast USD 511.48 M), actual EPS USD -0.14 (forecast USD -0.5466)

ICU Medical released FY2025 9 Months earnings on November 6 After-Market (EST), actual revenue USD 1.691 B, actual EPS USD 0.6593

ICU Medical to Release FY2025 Q3 Earnings on November 6 After-Market EST, Forecast Revenue USD 511.48 M, EPS USD -0.5466

ICU Medical released FY2025 Q2 earnings on August 7 After-Market EST, actual revenue USD 548.87 M (forecast USD 540.38 M), actual EPS USD 1.43 (forecast USD -0.785)

ICU Medical released FY2025 Semi-Annual earnings on August 7 After-Market EST, with actual revenue of USD 1.154 B and EPS of USD 0.8

ICU Medical to release FY2025 Q2 earnings report on August 7 During-Market EST, forecast revenue USD 543.4 M, EPS USD -0.7566

Virginia Ruth Sanzone Sells ICU Medical Stock

ICU Medical COO Sells Shares

Squarepoint Ops LLC Increases ICU Medical Stock Holdings

ICU Medical COO Disposes of Ordinary Shares

ICU Medical Inc. Director Sells Company Shares

ICU Medical COO Disposes of Common Stock

ICU Medical Holds Annual General Meeting

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

ICUI

Gabelli Funds LLC reduced its stake in ICU Medical, Inc. by 13.2%, selling 10,400 shares during Q4, now holding 68,600 shares valued at approximately $9.79 million. Other investors, including Covestor Ltd and Strs Ohio, increased their stakes. ICU Medical's stock opened at $123.66, with a market cap of $3.09 billion. The company reported Q1 earnings of $1.97 per share, exceeding estimates, but revenue declined 12.3% year-over-year. Analysts have mixed ratings, with a consensus 'Buy' and a target price of $169.00.

Market Beat

Piper Sandler Cos

KeyCorp

Jefferies Financial

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

Gabelli Funds LLC Sells 10,400 Shares of ICU Medical, Inc. $ICUI

ICU Medical shareholders approved governance amendments at the annual meeting, shifting to simple majority voting and allowing 25% shareholders to call special meetings. All director nominees were re-elected, and Deloitte & Touche was reappointed as auditor. A proposal for a 10% special meeting right was rejected, indicating a preference for controlled shareholder rights. Analyst ratings for ICUI stock are mixed, with a Buy rating and a price target of $164.00, while Spark's AI Analyst rates it as Neutral due to improving financials but concerns over revenue contraction.

Tip Ranks

ICU Medical Enhances Governance with New Shareholder Rights

SBIO

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

nasdaq

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

SPDR S&P Health Equip

ALPS Medical Breakthrough

iShares US Medical Devices

Nasdaq

ICU Medical (ICUI) Q1 2026 Earnings Transcript

ICU Medical (ICUI) reported Q1 2026 revenue of $526 million, reflecting a 1% organic growth. Gross margins improved to over 41%, with adjusted EBITDA at $99 million and EPS at $1.97. The IV Systems business grew 8% reported. The company anticipates free cash flow close to $150 million for the year, despite facing tariff expenses and increased testing requirements from the FDA. The outlook remains consistent with previous guidance, and the company expects lower tariffs in upcoming quarters.

ICU Medical reiterates full-year view while targeting close to $150M free cash flow

ICU Medical, Inc. (NASDAQ:ICUI) has received an average "Buy" rating from five research firms. One analyst rated it as a sell, while two rated it as a buy and two as a strong buy. The average 12-month price target is $169. Recent reports show mixed analyst opinions, with Jefferies upgrading to "strong-buy" and Piper Sandler lowering their target price. Institutional investors hold 96.10% of the stock. Despite a Q1 earnings beat, revenue declined by 12-14% year-over-year, raising concerns about growth and margins.

Federated Hermes

Schroders PLC

ICU Medical, Inc. (NASDAQ:ICUI) Given Average Rating of "Buy" by Analysts

Earnings Watch

ICU Medical | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 530.23 M

ICU Medical (NASDAQ:ICUI) has updated its FY 2026 earnings guidance, projecting EPS between 7.750 and 8.450, slightly above the consensus estimate of 7.740. The company’s stock performance showed a rise of $3.48, reaching $123.07, with a market cap of $3.08 billion. Analysts have mixed ratings on the stock, with a consensus rating of "Moderate Buy" and an average target price of $169.00. Institutional investors hold 96.10% of the company's shares, reflecting strong institutional interest in ICU Medical.

ICU Medical (NASDAQ:ICUI) Updates FY 2026 Earnings Guidance

ICU Medical(ICUI.US)